Title: Elephant in the room; Comparing total cholesterol, HDL-C and their ratio among ischemic and hemorrhagic stroke

Abstract

Scope and background: Every year more than 7,95,000 people in USA are victims of cerebrovascular accident, majority being ischemic. There is hypothesis that lipid abnormalities have modifiable risk relationship with stroke subtypes. Elephant in the room; Comparing total cholesterol, HDL-C and their ratio among ischemic and hemorrhagic stroke. Study Design: An observational prospective comparative study. Methodology: Hundred patients between 30 to 90 years of age, admitted in BVH Bahawalpur with first ever CVA and verified by CT scan brain, were included in the study. Patients with history of coronary heart disease or lipid lowering drugs, epilepsy, infective or metastatic disorder, or pre-existing cognitive defects, were excluded from this study. A medical history with neurological examination was recorded and subjects were broadly divided in 50 each participant of ischemic (group A) and hemorrhagic (group B) subtypes. Fasting total cholesterol (TC), high density lipoproteins (HDL-C) and triglycerides (TGs)of both groups were collected and mean values of quantitative data were presented as mean SD [standard deviation].The lipid values were interpreted in normal or high-risk category by applying NCEP ATPIII criterion. Frequency percentage of values was determined and compared using proportion test taking p-value of < 0.05 as significant. Results: Quantitative lipoprotein data showed that in group A (ischemic CVA), mean TC was 218.30 ± 79mg/dl and raised above normal reference range. While it was 194± 26.7mg/ dl in hemorrhagic cases (highly significant at P value of < 0.001). The mean HDL concentration was 33.10± 7.33mg/dl in patients of ischemic stroke while it was 40.02-4.22 in hemorrhagic cases (p value o.oo2, highly significant). Serum TGs levels turned out to be normal in both groups. Conclusion: Hypercholesterolemia and low HDLC was seen significantly in ischemicCVA group as compared to hemorrhagic counterpart so needing timely preventive lipid lowering strategies.

+1 (506) 909-0537